Resources for coping with cancer during COVID-19. Learn More

Cabazitaxel (Jevtana®)

Common name: Cabazitaxel
Brand name: Jevtana®

What is Cabazitaxel?

Cabazitaxel is a chemotherapy drug used to treat advanced (metastatic) prostate cancer when hormonal therapy is no longer able to control the cancer. Cabazitaxel, used in combination with a corticosteroid (such as prednisone or prednisolone), is often given to men after they have been treated with docetaxel, another chemotherapy drug.

How is Cabazitaxel administered?

Cabazitaxel is administered by injection.

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received cabazitaxel. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Anemia (low red blood cell count)
  • Bruising / bleeding    
  • Blood in urine (hematuria)
  • Constipation    
  • Diarrhea            
  • Fatigue
  • Infection
  • Kidney problems
  • Loss of appetite
  • Muscle weakness
  • Neutropenia (low white blood cell count)
  • Numbness / tingling in hands and feet

Is Cabazitaxel covered in my province or territory?   

Cabazitaxel is covered by provincial drug programs in:
  • Alberta
  • British Columbia (restricted)
  • Ontario
  • Newfoundland & Labrador
  • Nova Scotia
  • Saskatchewan
Cabazitaxel is not covered by provincial drug programs in:
  • New Brunswick
  • Prince Edward Island
  • Quebec
  • Nunavut
  • Northwest Territories
  • Yukon
Cabazitaxel may be covered by provincial drug programs after individual review in:
  • ​Manitoba​

Last Reviewed: July 2017


Rock the Road Raffle 2021

Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation

February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation.

1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.

Click here for news archive